Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy

Status Completed

Clinical Trial Summary

More than 70% of birch pollen allergic patients suffer from allergic reactions to certain foods, e.g. stone fruits, hazelnut and some vegetables. However, specific immunotherapy (SIT) with birch pollen extract is not effective for the treatment of associated food allergy in a substantial number of patients. Based on our previous clinical and immunological investigations of birch pollen related food allergy (BPRFA) the investigators hypothesize that for effective SIT of this abundant food allergy the disease-eliciting food allergens should be employed. To prove this concept, the investigators aim to sublingually administer the major apple allergen, Mal d 1, to birch pollen-allergic patients with concomitant apple allergy and evaluate clinical and immunological effects of this treatment. The investigators choose Mal d 1 as model food allergen because (i) its cross-reactivity with Bet v 1 has been well characterized,(ii) apple is the most frequent trigger for BPRFA and (iii) recombinant(r)Mal d 1 was well tolerated after sublingual administration to 20 birch pollen-allergic patients in a previous study. Sublingual administration of a defined concentration of GMP-rMal d 1 will be compared with equal doses of GMP-rBet v 1 as a positive control and placebo-treatment. Clinical parameters will include skin prick tests (SPT) and objective and subjective assessment of apple and birch pollen-induced allergic symptoms. Immunological parameters will comprise the analysis of antibody and T cell responses to Mal d 1 and Bet v 1 as well as the evaluation of basophil activation.

The proposed pilot study will be a first investigation of the concept to specifically treat BPRFA with the involved food allergens and thus, represents an important step in the development of an efficient and safe therapy in the future.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01449786
Study type	Interventional
Source	Medical University of Vienna
Contact
Status	Completed
Phase	Phase 2
Start date	March 14, 2012
Completion date	December 20, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06037148` - Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants	Phase 1
Completed	`NCT04912076` - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen	Phase 1
Recruiting	`NCT05346718` - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis	N/A
Completed	`NCT01137357` - Probiotics for Reduction Of Markers In Subjects With Allergy	N/A
Active, not recruiting	`NCT05668390` - Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma	Phase 3
Not yet recruiting	`NCT02146300` - Effect of the Nasal Provocation on the Breathing Style	N/A
Completed	`NCT03969849` - Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants	Phase 1
Completed	`NCT04435678` - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens	N/A
Completed	`NCT01628484` - Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation	Phase 1
Completed	`NCT00932607` - SUBLIVAC® Birch PROBE Study	Phase 2
Completed	`NCT00266526` - Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV	Phase 2
Completed	`NCT02143583` - Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment	Phase 2
Completed	`NCT02074930` - Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure	N/A
Completed	`NCT04266028` - Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy	Phase 1
Completed	`NCT00309062` - Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis	Phase 3
Completed	`NCT01675791` - A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet	Phase 2